Reijo Laaksonen1,2,3. 1. Zora Biosciences Oy, Biologinkuja 1, 02150, Espoo, FI, Finland. reijo.laaksonen@zora.fi. 2. Medical School, University of Tampere, Tampere, Finland. reijo.laaksonen@zora.fi. 3. Finnish Clinical Biobank, University Hospital of Tampere, Tampere, Finland. reijo.laaksonen@zora.fi.
Abstract
PURPOSE: This systematic review was performed to summarize published data on lipidomic and metabolomic risk markers of coronary artery disease. METHODS: Studies were identified from a literature search of PubMed. RESULTS: Published data shows that analysis of metabolites and lipids offers an opportunity to increase our knowledge of the biological processes related to development and progression of atherosclerotic coronary disease. It is evident that advanced analytical technologies are able to detect and identify a large number of molecules that may have important structural and functional roles over and above currently used biomarkers in the cardiovascular field. It is suggested in a number of reports that the novel biomarkers can be used to improve risk stratification and patient selection for different treatments. Also, monitoring treatment efficacy and safety as well as lifestyle changes should be facilitated by such novel markers. CONCLUSION: Until now a plethora of biomarker candidates associated with cardiovascular event risk have been identified, but very few have passed through clinical and analytical validation and found their way into clinical use. Consequently, the appetite of physicians to use these novel tests in daily clinical routine has not yet been truly tested.
PURPOSE: This systematic review was performed to summarize published data on lipidomic and metabolomic risk markers of coronary artery disease. METHODS: Studies were identified from a literature search of PubMed. RESULTS: Published data shows that analysis of metabolites and lipids offers an opportunity to increase our knowledge of the biological processes related to development and progression of atherosclerotic coronary disease. It is evident that advanced analytical technologies are able to detect and identify a large number of molecules that may have important structural and functional roles over and above currently used biomarkers in the cardiovascular field. It is suggested in a number of reports that the novel biomarkers can be used to improve risk stratification and patient selection for different treatments. Also, monitoring treatment efficacy and safety as well as lifestyle changes should be facilitated by such novel markers. CONCLUSION: Until now a plethora of biomarker candidates associated with cardiovascular event risk have been identified, but very few have passed through clinical and analytical validation and found their way into clinical use. Consequently, the appetite of physicians to use these novel tests in daily clinical routine has not yet been truly tested.
Authors: Juho-Pekka Karjalainen; Nina Mononen; Nina Hutri-Kähönen; Miikael Lehtimäki; Mika Hilvo; Dimple Kauhanen; Markus Juonala; Jorma Viikari; Mika Kähönen; Olli Raitakari; Reijo Laaksonen; Terho Lehtimäki Journal: J Lipid Res Date: 2019-07-03 Impact factor: 5.922
Authors: Marieke Loef; Johannes H von Hegedus; Mohan Ghorasaini; Féline P B Kroon; Martin Giera; Andreea Ioan-Facsinay; Margreet Kloppenburg Journal: Metabolites Date: 2020-12-31
Authors: Sven W Meckelmann; Jade I Hawksworth; Daniel White; Robert Andrews; Patricia Rodrigues; Anne O'Connor; Jorge Alvarez-Jarreta; Victoria J Tyrrell; Christine Hinz; You Zhou; Julie Williams; Maceler Aldrovandi; William J Watkins; Adam J Engler; Valentina Lo Sardo; David A Slatter; Stuart M Allen; Jay Acharya; Jacquie Mitchell; Jackie Cooper; Junken Aoki; Kuniyuki Kano; Steve E Humphries; Valerie B O'Donnell Journal: Circ Genom Precis Med Date: 2020-05-12